rep 9ac AT EASL, Berlin 1 April 2011 - But nothing new!

StephenW

REP9AC在欧洲肝病学会柏林2011年4月1日, 但没有新的资料.

http://www1.easl.eu/easl2011/program/Orals/339.htm
Oral Presentations    Session Title: Parallel Session:HEPATITIS B
Presentation Date: 01 APR, 2011
REP 9AC IS A POTENT HBSAG RELEASE INHIBITOR WHICH CLEARS SERUM HBSAG AND ELICITS SVRS IN PATIENTS WITH CHRONIC HEPATITIS B

M. Al-Mahtab1, M. Bazinet2, A. Vaillant2*
1Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, 2REPLICor Inc., Montreal, QC, Canada. *[email protected]

Background: HBsAg plays a role in suppressing the immune system and may allow maintenance of chronic liver infection. REP 9AC inhibits the release of HBsAg from infected hepatocytes. In preclinical studies surface antigen seroclearance occurred after two weeks of treatment and four weeks of treatment resulted in 55% of animals achieving a durable SVR. REP 9AC is currently being evaluated in patients with chronic HBV in a proof of concept clinical trial. An updated report on interim clinical trial data will be presented.
Methods: Patients were HBsAg+ with pre-treatment HBV DNA titers between 106 and 1012 copies/ml and had significant liver fibrosis. Safety and virologic response (HBV DNA, HBsAg, anti-HBs) were assessed at the trial site and by confirmatory testing (HBsAg, HBeAg, anti-HBs, anti-HBe) of frozen serum samples using the Architect ™ testing platform.
Results: At the time of abstract submission, 5 of 8 patients treated have cleared serum HBsAg as early as 7 days and no later than 15 weeks following initiation of treatment at higher doses. Anti-HBsAg antibodies have been observed in 7 out of 8 patients. Six, patients have achieved a 3 to 7 log reduction in their HBV DNA titers from pre-treatment levels after 7-13 weeks of treatment and three of these patients have achieved complete control of their infection after 20-27 weeks of treatment (HBV DNA -, HBsAg -, HBeAg -, anti-HBs +, anti-HBe +) and are being followed off treatment. These 3 patients are currently maintaining control over their infections 14, 27 and 52 weeks after stopping treatment.
Conclusions: REP 9AC can rapidly clear serum HBsAg in infected patients which appears to allow the restoration of an effective immune response, leading to the achievement of SVRs in three patients to date. These results suggest that REP 9AC may become an important new tool in the treatment of chronic hepatitis B.

(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

StephenW

口头报告

会议名称：平行会议：乙型肝炎
颁奖日期：2011年4月1日
回港证9AC是一种强效释放抑制剂，清除乙肝表面抗原血清HBsAg和抒发在慢性肝炎患者SVRS乙

米铝Mahtab1，米Bazinet的二，答：2 *威能
谢赫穆吉布医科大学1Bangabandhu，达卡，孟加拉国，2REPLICor公司，蒙特利尔，QC，加拿大。 * [email protected]

背景：乙肝表面抗原中起着抑制免疫系统的作用，并可能允许慢性肝病感染维修。回港证9AC抑制感染的肝细胞表面抗原的释放。在临床前研究表面抗原血清廓清发生经过两个星期的治疗和四个星期的治疗，在55个实现持久的SVR％动物的结果。回港证9AC目前正在评估慢性乙肝在临床试验证明概念的患者。对中期临床试验数据的最新报告将提交。
方法：患者乙肝表面抗原+与治疗前HBV DNA的滴度在106和1012拷贝/ ml和肝纤维化有显着的。安全和病毒学应答（乙肝病毒脱氧核糖核酸，乙肝表面抗原，抗- HBs）进行了评估，并在审判现场验证性测试用的冷冻血清测试平台建筑师™样本（乙肝表面抗原，e抗原，抗- HBs，抗- HBe）。
结果：在抽象的提交时间，8个已清除治疗的患者5早7天，不晚于15周后开始治疗在高剂量血清乙肝表面抗原。抗HBsAg抗体已观察了8例7。六，患者治疗后取得7-13和这些病人在三个星期HBV DNA的滴度从3日至7日志治疗前水平下降，取得20-27周的治疗后（其感染HBV DNA的完全控制 - ，乙肝表面抗原 - ，e抗原 - ，抗- HBs +，抗- HBe +），并正在遵循了治疗。这3例患者目前保持对他们的感染14，27和52周治疗后停止控制。
结论：回港证9AC能迅速清除感染的患者血清乙肝表面抗原这似乎允许恢复有效的免疫反应，导致患者在三日至SVRs成就。这些结果表明，回港证9AC可能成为治疗慢性乙型肝炎的一个重要的新工具

cshbv

StephenW 发表于 2011-4-3 23:26
REP9AC在欧洲肝病学会柏林2011年4月1日, 但没有新的资料.

http://www1.easl.eu/easl2011/program/Orals/ ...

不是完全没有新的资料吧，对病人的描述好像详细一些了。至少不是说急性的了。

^.^

nothing new……

mingbai

为什么不大量实验？用中国的试验者

hengyang

可信度不高,想治好乙肝还要等个50年左右吧

ainile

去你的，别泼冷水！！！

hunterpt

上次新闻是 10月28号 2010   这样子算下来 有5个月了 无任何新闻有点怪。   

hunterpt

上次新闻是 10月28号 2010   这样子算下来 有5个月了 无任何新闻有点怪。   

非东亚病夫

REP 我早就失望了。